Aphios Gets NCI Contract for Manufacturing & Formulation of Natural Anticancer Drug for Melanoma
May 07, 2002
Woburn, MA — Aphios Corporation has been awarded Phase II of a Fast Track SBIR contract entitled "SuperFluids™ Isolation of Natural Anticancer Drugs" from the National Cancer Institute (NCI), National Institutes of Health (NIH) to manufacture and formulate a specific "difficult-to-manufacture and difficult-to-formulate" natural anticancer molecule for clinical trials against melanoma. This Fast Track SBIR contract is entirely financed by Federal funds ($850,000).

SuperFluids™ are near-critical, critical or supercritical fluids with or without polar cosolvents. These fluids are normally gases, such as carbon dioxide, which when compressed, exhibit enhanced thermodynamic properties of penetration, solvation and expansion. Aphios has developed and patented SuperFluids™ technologies for the manufacturing as well as nanosomal formulation of hydrophobic anticancer drugs such as paclitaxel (the active ingredient in Taxol®), Bryostatin 1 and camptothecin.

Aphios Corporation is a biopharmaceutical company that is developing enhanced natural therapeutics for health maintenance and the treatment of human diseases with a focus on infectious diseases and oncology. The Company has developed several enabling SuperFluids™ technology platforms for improving the discovery, manufacturing, delivery and safety of therapeutic drugs, and has several enhanced therapeutic drugs in development. Aphios' product pipeline includes small pharmaceutically active molecules from medicinal plants and marine organisms, and large protein macromolecules that are crucial to the functioning of the human genome.



Taxol® is a registered trademark of the Bristol-Myers Squibb Company